Envista (NYSE:NVST) Price Target Raised to $27.00

Envista (NYSE:NVST) had its price target lifted by Stifel Nicolaus from $25.00 to $27.00 in a research report sent to investors on Wednesday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Robert W. Baird set a $27.00 price objective on shares of Envista in a research note on Friday, October 31st. Wall Street Zen raised Envista from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 26th. Piper Sandler lifted their price target on Envista from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Friday, January 30th. JPMorgan Chase & Co. increased their price objective on Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 16th. Finally, Evercore restated an “outperform” rating on shares of Envista in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $26.50.

Envista Trading Up 18.0%

Shares of NVST opened at $29.17 on Wednesday. The business’s 50-day moving average price is $22.80 and its 200 day moving average price is $21.23. The stock has a market capitalization of $4.80 billion, a P/E ratio of 104.18, a P/E/G ratio of 1.10 and a beta of 1.01. Envista has a 1-year low of $14.22 and a 1-year high of $29.28. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. The company had revenue of $750.60 million during the quarter, compared to analyst estimates of $680.26 million. Envista had a net margin of 1.73% and a return on equity of 6.55%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Analysts expect that Envista will post 1 earnings per share for the current year.

Institutional Investors Weigh In On Envista

Several institutional investors have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in Envista by 26.6% in the first quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock worth $401,000 after buying an additional 4,885 shares during the last quarter. Millennium Management LLC increased its stake in shares of Envista by 218.6% during the 1st quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock worth $6,627,000 after purchasing an additional 263,442 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Envista by 39.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock valued at $10,859,000 after purchasing an additional 177,630 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Envista by 15.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock valued at $9,821,000 after purchasing an additional 76,246 shares during the last quarter. Finally, KLP Kapitalforvaltning AS boosted its holdings in Envista by 11.3% in the second quarter. KLP Kapitalforvaltning AS now owns 36,400 shares of the company’s stock worth $711,000 after purchasing an additional 3,700 shares in the last quarter.

Key Headlines Impacting Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 results beat expectations — Envista reported $0.38 EPS vs. $0.32 consensus and revenue of $750.6M versus ~ $680M est., with revenue up ~15% year-over-year. Strong results are the primary driver of the move higher. Envista Reports Fourth Quarter 2025 Results
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $1.35–$1.45 vs. consensus ~ $1.27 — the stronger outlook (and beat + guidance combo) is supportive of the rally and suggests better-than-expected near-term growth. Press Release / Slide Deck
• Neutral Sentiment: Earnings materials and call transcripts are available for deeper read — the conference call transcript and slide deck provide management commentary on drivers (product mix, geographic trends, margins) that investors should review to judge sustainability. Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Wall‑street writeups and snapshots (Zacks, Yahoo, Investing) highlight the beat and value/Growth characteristics — useful for screening but not new catalysts by themselves. Zacks Q4 Metrics
• Negative Sentiment: Analyst targets still imply downside — JPMorgan and Wells Fargo both raised targets to $26 but kept neutral/equal‑weight ratings; those $26 targets sit below the current market level, which could cap upside or prompt caution once headline momentum fades. Benzinga – JPMorgan Benzinga – Wells Fargo

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.